ID: ALA2323442

Max Phase: Preclinical

Molecular Formula: C17H20N2O6

Molecular Weight: 348.36

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(=O)O[C@H]1C[C@@H]2C[C@@H](OC(=O)c3ccccc3[N+](=O)[O-])C[C@@H]1N2C

Standard InChI:  InChI=1S/C17H20N2O6/c1-10(20)24-16-8-11-7-12(9-15(16)18(11)2)25-17(21)13-5-3-4-6-14(13)19(22)23/h3-6,11-12,15-16H,7-9H2,1-2H3/t11-,12+,15-,16-/m0/s1

Standard InChI Key:  FSGYKLAGSGORJN-VZAMPYOESA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 348.36

Molecular Weight (Monoisotopic): 348.1321

AlogP: 1.92

#Rotatable Bonds: 4

Polar Surface Area: 98.98

Molecular Species: NEUTRAL

HBA: 7

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 8.15

CX LogP: 1.76

CX LogD: 0.95

Aromatic Rings: 1

Heavy Atoms: 25

QED Weighted: 0.47

Np Likeness Score: 0.79

References

1. Wang ZP, Liu HZ, Zhu L, Hu YM, Cui YY, Niu YY, Lu Y, Chen HZ..  (2013)  The effect of absolute configuration on activity, subtype selectivity (M3/M2) of 3α-acyloxy-6β-acetoxyltropane derivatives as muscarinic M3 receptor antagonists.,  21  (5): [PMID:23375092] [10.1016/j.bmc.2012.12.052]

Source

Source(1):

• Scientific Literature